Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma.

Archives of endocrinology and metabolism - 18 May 2021

Scheffel Rafael Selbach, de Cristo Ana Patrícia, Romitti Mirian, Vargas Carla Vaz Ferreira, Ceolin Lucieli, Zanella André B, Dora Jose Miguel, Maia Ana Luiza

Abstract excerpt

OBJECTIVE: Although the prognostic role of BRAFV600E mutation in papillary thyroid carcinoma (PTC) is controversial, the American Thyroid Association (ATA) includes the mutational status in their risk stratification system. To evaluate the impact of the BRAFV600E mutation status on PTC risk stratification. METHODS: PTC patients attending a university-based hospital who had the analysis of the BRAFV600E mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Share to Risk Assessment

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34033285
DOI: 10.20945/2359-3997000000285
PMCID: PMC10528629

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma.PMID 34033285Read ↗

Response to therapy of papillary thyroid cancer of known BRAF status.Semantic proximity Read ↗

BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.Semantic proximity Read ↗

The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome.Semantic proximity Read ↗

The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.Semantic proximity Read ↗

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.Semantic proximity Read ↗

Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer.Semantic proximity Read ↗

BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrenceSemantic proximity Read ↗

Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma.Semantic proximity Read ↗

Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.Semantic proximity Read ↗

The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.Semantic proximity Read ↗

BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma.Semantic proximity Read ↗

Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.